<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T20:10:02Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/6703" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/6703</identifier><datestamp>2025-10-24T10:32:39Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Benchmarking the Extent and Speed of Reperfusion: First Pass TICI 2c-3 Is a Preferred Endovascular Reperfusion Endpoint</dc:title>
   <dc:creator>Yoo, Albert J.</dc:creator>
   <dc:creator>Soomro, Jazba</dc:creator>
   <dc:creator>Andersson, Tommy</dc:creator>
   <dc:creator>Saver, Jeffrey L.</dc:creator>
   <dc:creator>Ribó Jacobi, Marc</dc:creator>
   <dc:creator>Bozorgchami, Hormozd</dc:creator>
   <dc:contributor>Institut Català de la Salut</dc:contributor>
   <dc:contributor>[Yoo AJ, Soomro J] Department of Neurointervention, Texas Stroke Institute, Fort Worth, TX, United States. [Andersson T] Neuroradiology, Karolinska University Hospital, Clinical Neuroscience Karolinska Institutet, Stockholm, Sweden. Medical Imaging, Allgemeine Ziekenhuis Groeninge, Kortrijk, Belgium. [Saver JL] Department of Neurology, University of California, Los Angeles, Los Angeles, CA, United States. [Ribo M] Unitat d’Ictus, Servei de Neurologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Bozorgchami H] Department of Neurology, Oregon Health and Science University Hospital, Portland, OR, United States</dc:contributor>
   <dc:contributor>Vall d'Hebron Barcelona Hospital Campus</dc:contributor>
   <dc:subject>Isquèmia cerebral - Tractament</dc:subject>
   <dc:subject>Reperfusió (Fisiologia)</dc:subject>
   <dc:subject>DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Brain Ischemia</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::/therapy</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Perfusion::Reperfusion</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::/methods</dc:subject>
   <dc:subject>ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos cerebrovasculares::isquemia cerebral</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::/terapia</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::perfusión::reperfusión</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::/métodos</dc:subject>
   <dc:description>Isquèmia cerebral; Trombectomia mecànica; Reperfusió</dc:description>
   <dc:description>Isquemia cerebral; Trombectomía mecánica; Reperfusión</dc:description>
   <dc:description>Brain ischaemia; Mechanical thrombectomy; Reperfusion</dc:description>
   <dc:description>Background and Purpose: End-of-procedure substantial reperfusion [modified Treatment in Cerebral Ischemia (mTICI) 2b-3], the leading endpoint for thrombectomy studies, has several limitations including a ceiling effect, with recent achieved rates of ~90%. We aimed to identify a more optimal definition of angiographic success along two dimensions: (1) the extent of tissue reperfusion, and (2) the speed of revascularization.&#xd;
Methods: Core-lab adjudicated TICI scores for the first three passes of EmboTrap and the final all-procedures result were analyzed in the ARISE II multicenter study. The clinical impact of extent of reperfusion and speed of reperfusion (first-pass vs. later-pass) were evaluated. Clinical outcomes included 90-day functional independence [modified Rankin Scale (mRS) 0–2], 90-day freedom-from-disability (mRS 0–1), and dramatic early improvement [24-h National Institutes of Health Stroke Scale (NIHSS) improvement ≥ 8 points].&#xd;
Results: Among 161 ARISE II subjects with ICA or MCA M1 occlusions, reperfusion results at procedure end showed substantial reperfusion in 149 (92.5%), excellent reperfusion in 121 (75.2%), and complete reperfusion in 79 (49.1%). Reperfusion rates on first pass were substantial in 81 (50.3%), excellent reperfusion in 62 (38.5%), and complete reperfusion in 44 (27.3%). First-pass excellent reperfusion (first-pass TICI 2c-3) had the greatest nominal predictive value for 90-day mRS 0–2 (sensitivity 58.5%, specificity 68.6%). There was a progressive worsening of outcomes with each additional pass required to achieve TICI 2c-3.&#xd;
Conclusions: First-pass excellent reperfusion (TICI 2c-3), reflecting rapid achievement of extensive reperfusion, is the technical revascularization endpoint that best predicted functional independence in this international multicenter trial and is an attractive candidate for a lead angiographic endpoint for future trials.</dc:description>
   <dc:description>Cerenovus sponsored the ARISE II study, and provided support for open access to this article.</dc:description>
   <dc:date>2021-12-16T13:20:21Z</dc:date>
   <dc:date>2021-12-16T13:20:21Z</dc:date>
   <dc:date>2021-05-11</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>Yoo AJ, Soomro J, Andersson T, Saver JL, Ribo M, Bozorgchami H, et al. Benchmarking the Extent and Speed of Reperfusion: First Pass TICI 2c-3 Is a Preferred Endovascular Reperfusion Endpoint. Front Neurol. 2021 May 11;12:669934.</dc:identifier>
   <dc:identifier>1664-2295</dc:identifier>
   <dc:identifier>https://hdl.handle.net/11351/6703</dc:identifier>
   <dc:identifier>10.3389/fneur.2021.669934</dc:identifier>
   <dc:identifier>34046008</dc:identifier>
   <dc:identifier>000653650500001</dc:identifier>
   <dc:identifier>http://hdl.handle.net/11351/6703</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Frontiers in Neurology;12</dc:relation>
   <dc:relation>https://doi.org/10.3389/fneur.2021.669934</dc:relation>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Frontiers Media</dc:publisher>
   <dc:source>Scientia</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>